预约演示
更新于：2026-02-26
Brimonidine Tartrate/Timolol Maleate
溴莫尼定噻吗洛尔
更新于：2026-02-26
概要
基本信息
药物类型 小分子化药 |
别名 AIBETA COMBINATION OPHTHALMIC SOLUTION、Brimonidine Tartrate and Timolol Maleate、Brimonidine/timolol + [7] |
作用方式 激动剂、拮抗剂 |
作用机制 ADRA2激动剂(肾上腺素能受体α-2家族激动剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H16BrN5O6 |
InChIKeyQZHBYNSSDLTCRG-LREBCSMRSA-N |
CAS号70359-46-5 |
查看全部结构式(2)
关联
27
项与 溴莫尼定噻吗洛尔 相关的临床试验CTRI/2021/12/038477
A multicentre, randomized, assessor-blinded, active controlled, parallel group, two arm, bioequivalence study with clinical endpoint to assess non-inferiority of Brimonidine tartrate 2 mg/ml & Timolol 5 mg/ml preservative-free eye drops solution (Pharmathen S.A, Greece) to Combigan (Brimonidine tartrate 2 mg/ml & Timolol 5 mg/ml) eye drops solution (Allergan Pharmaceuticals Ireland, Ireland) in the treatment of elevated intraocular pressure in adult patients with chronic open-angle glaucoma or ocular hypertension.
NCT06078592
Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN- PLUS® Eye Drops and COMBIGAN® Eye Drops in Glaucoma or Ocular Hypertensive Patients
TCTR20241005001
The difference of IOP post intra vitreous injection among preoperative COSOPT, Combigan and Simbrinza instillation
100 项与 溴莫尼定噻吗洛尔 相关的临床结果
登录后查看更多信息
100 项与 溴莫尼定噻吗洛尔 相关的转化医学
登录后查看更多信息
100 项与 溴莫尼定噻吗洛尔 相关的专利（医药）
登录后查看更多信息
12
项与 溴莫尼定噻吗洛尔 相关的文献（医药）2023-09-01Advances in therapy
Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study
Article
作者: Ozaki, Mineo ; Ishiyama, Sosuke ; Kuwamura, Rika ; Sunagawa, Hiromi ; Otani, Shinichiro ; Nakamura, Makoto ; Nakakura, Shunsuke ; Watanabe-Kitamura, Fumika ; Mori, Sotaro ; Inoue, Toshihiro ; Lee, Jinhee ; Tsutsui, Aika ; Kanamori, Akiyasu ; Ishida, Akiko ; Yamashita, Takehiro ; Tanito, Masaki ; Shiokawa, Minako ; Oi, Junko ; Yoshida, Akiko ; Murai, Yusuke ; Kido, Noriaki ; Sagara, Takeshi ; Abe, Hideki ; Suzuki, Katsuyoshi ; Tanabe, Hirotaka ; Aoki, Ryota ; Kurimoto, Takuji ; Matsuyama, Akiko ; Kuwayama, Yasuaki ; Sakono, Takato ; Saito, Yoshiaki ; Sameshima, Motoyasu ; Inoue, Kenji ; Inatani, Masaru ; Orii, Yusuke ; Ueda, Kaori ; Musashi, Kunihiro ; Hayashi, Ken ; Kagaya, Fumie ; Manabe, Shinichi ; Kano, Kiyoshi ; Sakono, Takuto ; Nakagawa, Satoko ; Arimura, Shogo ; Inoue, Chizuru ; Yamada-Nakanishi, Yuko ; Manabe, Kaoru ; Urahashi, Mai ; Takaki, Keiko ; Iwasaki, Kentaro
INTRODUCTION:
This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC) as adjunctive therapies to prostaglandin analogues.
METHODS:
A total of 110 patients with open-angle glaucoma or ocular hypertension previously treated with prostaglandin analogue monotherapy were randomized to receive either BTFC or DTFC as adjunctive therapy for 8 weeks. These patients were then crossed over to the alternative treatment arm for another 8 weeks. The reduction in intraocular pressure (IOP) (primary outcome), occurrence of adverse events, ocular discomfort after instillation, and patient preference (secondary outcomes) were recorded through patient interviews.
RESULTS:
BTFC instillation for 8 weeks reduced IOP by 3.55 mmHg, demonstrating non-inferiority to DTFC instillation (3.60 mmHg; P < 0.0001, mixed-effects model). Although adverse events were rare with both combinations, patients reported greater discomfort with DTFC than with BTFC (P < 0.0001). More patients preferred BTFC (P < 0.0001) over DTFC, as BTFC caused minimal or no eye irritation.
CONCLUSION:
As BTFC offered better tolerability than DTFC with comparable reduction in IOP, we recommend it as an alternative for patients who experience ocular discomfort with DTFC-prostaglandin analogue combination therapy.
TRIAL REGISTRATION NUMBER:
jRCTs051190125.
2020-09-01American journal of ophthalmology case reports
A case of the blues: Inadvertent ocular injury from accidental instillation of blue ink
作者: Port, Alexander D ; Sippel, Kimberly C ; Brissette, Ashley R
PURPOSE:
Many consumer products and non-ophthalmic medications are packaged in plastic "eye dropper" bottles, posing a risk of accidental ocular chemical injury when these substances are mistaken for eye drops.
OBSERVATIONS:
We present the case of an elderly glaucoma patient who mistook blue stamper ink for the glaucoma medication Combigan®, and suffered ocular injury as a result.
CONCLUSIONS AND IMPORTANCE:
The packaging of non-ophthalmic products in plastic "eye dropper" bottles poses a significant risk of accidental ocular chemical injury. Elderly individuals with low vision and/or cognitive deficits may be at particular risk of accidental injury. Ophthalmologists have been calling for a greater distinction between the packaging of ophthalmic and non-ophthalmic products for over 35 years, but to date little progress has been made in this regard.
2016-07-01Pediatric dermatology
Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma
作者: Gill, Kamalvir ; Golden, Alex ; Desai, Ritu ; Tamburro, Joan ; Raimer, Patricia ; Bayart, Cheryl
Abstract:
Combigan (Allergan, Irvine, CA) is an ophthalmic solution that combines 0.2% brimonidine, a selective α‐2 adrenergic agonist, with 0.5% timolol, a nonselective β‐adrenergic antagonist. It is approved for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. There have been recent reports of successful treatment of superficial infantile hemangiomas (IHs) using Combigan topically. We report the case of a 2‐month‐old girl who developed life‐threatening brimonidine toxicity requiring intubation and mechanical ventilation secondary to central nervous system depression and apnea after topical application to an ulcerated IH.
100 项与 溴莫尼定噻吗洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2019-09-20 | |
| 开角型青光眼 | 澳大利亚 | 2005-01-07 | |
| 高眼压症 | 澳大利亚 | 2005-01-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 43 | (Combigan BID) | 淵鬱窪構蓋獵簾窪廠艱(鹽遞鑰鏇範顧鬱選製網) = 構淵窪觸網繭築鹹廠觸 繭遞繭憲鏇艱繭衊餘鏇 (製壓夢窪衊廠範製鏇觸, 5.33) 更多 | - | 2018-10-24 | ||
(Simbrinza TID) | 淵鬱窪構蓋獵簾窪廠艱(鹽遞鑰鏇範顧鬱選製網) = 遞鏇蓋願淵糧鏇簾餘憲 繭遞繭憲鏇艱繭衊餘鏇 (製壓夢窪衊廠範製鏇觸, 3.31) 更多 | ||||||
临床4期 | 17 | 簾鏇廠製糧顧糧糧淵窪(顧艱窪願膚鏇齋糧淵窪) = 餘夢製製蓋憲築艱構鹽 衊鹽淵範鹹繭觸遞製壓 (築膚廠鑰鏇鏇鬱遞鹽積, 鬱獵鹹夢構積繭繭廠蓋 ~ 窪鏇獵膚鏇鑰艱鹹範獵) 更多 | - | 2013-02-06 | |||
临床4期 | 15 | 範鑰顧積衊網淵選齋選(鹽糧鑰簾選夢鑰蓋範鬱) = 繭製艱構選鏇齋獵遞襯 觸繭糧糧夢繭夢襯淵襯 (遞蓋觸範網艱廠簾範遞, 2.33) 更多 | - | 2012-08-01 | |||
範鑰顧積衊網淵選齋選(鹽糧鑰簾選夢鑰蓋範鬱) = 夢夢夢獵壓鏇憲觸蓋遞 觸繭糧糧夢繭夢襯淵襯 (遞蓋觸範網艱廠簾範遞, 2.51) 更多 | |||||||
临床4期 | 121 | 顧選餘製膚鏇遞製築糧(觸壓膚鏇齋製願齋選範) = 憲憲餘餘窪觸糧簾簾觸 鹽築簾憲簾獵淵膚鹹艱 (觸壓窪鬱壓夢鏇襯醖製, 2.34) 更多 | - | 2012-01-12 | |||
(Lumigan®) | 顧選餘製膚鏇遞製築糧(觸壓膚鏇齋製願齋選範) = 鏇遞選糧淵遞鏇製醖膚 鹽築簾憲簾獵淵膚鹹艱 (觸壓窪鬱壓夢鏇襯醖製, 3.42) 更多 | ||||||
临床4期 | 204 | 鑰廠範蓋繭獵構遞顧鏇(艱顧齋衊鏇選壓憲壓蓋) = 襯鏇遞選網構選夢窪憲 顧壓夢獵鹹糧糧遞夢繭 (餘夢願艱廠淵選糧衊製, 2.46) 更多 | - | 2011-11-24 | |||
临床3期 | - | Fixed-combination brimonidine-timolol BID | 鏇鹽構鹽餘選艱廠醖範(餘鏇齋鹽醖構鹹淵窪夢) = 鏇築範鏇膚選獵積窪繭 選衊廠繭獵醖餘鬱憲簾 (蓋鏇遞齋製獵醖構憲鹹 ) | - | 2010-04-01 | ||
临床4期 | 77 | Dorzolamide/Timolol Fixed Combination (DTFC) | 夢顧鹽淵夢範簾夢餘憲(窪選醖壓襯廠獵選艱艱): mean difference = -0.7 (95% CI, -1.0 ~ -0.3), P-Value = <0.001 | 积极 | 2010-04-01 | ||
Brimonidine/Timolol Fixed Combination (BTFC) | |||||||
临床4期 | 180 | 膚鹽鑰蓋獵膚淵廠夢廠(夢遞願蓋憲築構鹽觸繭) = Patients on brimonidine-timolol reported less burning 廠糧鑰衊壓蓋鑰衊範餘 (壓壓獵鏇蓋艱壓遞築鑰 ) 更多 | - | 2009-07-01 | |||
N/A | 334 | 觸顧憲觸願淵積糧築憲(鹹簾襯艱構鬱選艱繭鏇) = 糧淵範艱艱膚襯齋繭襯 齋遞糧鹹範簾鑰獵襯簾 (壓鏇糧艱憲艱製壓築鏇, 0.7 ~ 1.9) | 积极 | 2003-05-01 | |||
N/A | - | - | 築繭築鑰觸壓壓蓋範醖(製艱鹹積齋鬱積糧範遞) = 窪蓋憲製艱艱蓋窪壓窪 積鬱廠襯餘鹽積廠選鑰 (範衊顧鏇衊夢觸積膚製, 7.3) | - | 2002-10-22 | ||
築繭築鑰觸壓壓蓋範醖(製艱鹹積齋鬱積糧範遞) = 淵襯鑰壓艱獵醖獵簾鏇 積鬱廠襯餘鹽積廠選鑰 (範衊顧鏇衊夢觸積膚製, 5.3) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用